Various exemplary methods, systems, and devices for blood flow are provided. In general, an implant can be configured to be implanted in bone and to delay clotting of blood flowing from the bone. The implant can include an anti-coagulation agent to delay the clotting of the blood. The anti-coagulation agent can be a coating on the implant, can be natural to a material forming the implant, or can be impregnated into a material forming the implant. In an exemplary embodiment, the implant is implanted in a bone in a surgical procedure for securing a soft tissue to bone, such as a rotator cuff repair procedure or an anterior cruciate ligament (ACL) repair procedure.

A prosthetic valve comprising a tubular shaped sheet member comprising an extracellular matrix (ECM) composition, the sheet member having a plurality of ribbons having proximal and distal ends, the distal ends of the ribbons projecting from the sheet member proximal end.

A catheter configured to release nitric oxide and chlorhexidine providing anti-platelet and antimicrobial properties is manufactured by impregnating a thermoplastic polyurethane catheter extrusion with a nitric oxide releasing compound and with chlorhexidine. Thereafter, the impregnated catheter extrusion is coated with a polyurethane coating comprising chlorhexidine and/or a nitric oxide releasing compound. In the impregnating step, the catheter extrusion may be exposed to a solvent having the nitric oxide releasing compound and chlorhexidine dissolved therein. The solvent is removed from the catheter extrusion. In the coating step, the impregnated catheter extrusion may be dip coated in a polymer solution comprising polyurethane and chlorhexidine and/or a nitric oxide releasing compound in a suitable solvent. The nitric oxide releasing compound, impregnated and/or coated, may be selected from s-nitroso-n-acetylpenicillamine (SNAP), s-nitrosoglutathione (GSNO), and mixtures thereof. The chlorhexidine, impregnated and/or coated, may be selected from chlorhexidine diacetate, chlorhexidine base, chlorhexidine gluconate, and mixtures thereof.

Adhesive wound dressing that comprises an absorbent matrix (A) adhering to the central portion of a polyurethane backing (B) having an adhesive layer for the skin, said matrix (A) comprising: a. a breathable and porous polyethylene film at the end designed to come into contact with the wound; b. an absorbent layer made of non-woven fabric adjacent to film a), said absorbent layer consisting of: i. 60-65% viscose ii. 25-30% polyester iii. 5-15% polypropylene; c. a layer of polyethylene inserted between layer b) and a layer d. of hydrophobic polystyrene, the latter being in contact with the central portion of polyurethane backing (B); wherein matrix (A) is impregnated with a solution of one or more polysaccharides or the salts thereof.

An absorbable iron-based device includes an iron-based matrix and degradable polyester in contact with the surface of the iron-based matrix. The mass fraction of a low-molecular-weight part of the degradable polyester is less than or equal to 5%, and the molecular weight of the low-molecular-weight part is less than 10,000; or the mass fraction of a residual monomer in the degradable polyester is less than or equal to 2%.

The present disclosure relates to methods of preparing personalized blood vessels, useful for transplantation with improved host compatibility and reduced susceptibility to thrombosis. Also provided are personalized blood vessels produced by the methods and use thereof in surgery.

Methods for forming an expandable tubular body having a plurality of braided filaments including a first filament including platinum or platinum alloy and a second filament including cobalt-chromium alloy. The methods include applying a first phosphorylcholine material directly on the platinum or platinum alloy of the first filament and applying a silane material on the second filament followed by a second phosphorylcholine material on the silane material on the second filament. The first and second phosphorylcholine materials each define a thickness of less than 100 nanometers.

Various embodiments relate to catheter locking solutions and catheter locking therapies with use of trisodium citrate and ethyl alcohol, and in particular 4.0 to 15.0 weight/volume % trisodium citrate as an anticoagulant component and/or an antibacterial component and 15.0 to 25.0 volume/volume % ethyl alcohol as an antibacterial component. Use of the catheter locking solution and catheter locking therapy can reduce treatment failure during medical procedures that may employ catheters to supply treatment by at least significantly reducing the risks associated with bloodstream infections, catheter system malfunction, emboli formation, patient discomfort, and patient illness. These benefits can be partially due to the synergistic antibacterial effects of the trisodium citrate and ethyl alcohol in solution, generating an effective catheter locking solution with minimal concentrations of ethyl alcohol.

The invention relates to a medical device for use in human vessels, in particular in the carotid artery, comprising: a self-expandable mesh structure which at least partially forms a curved wall, and has, in a radially compressed state, a cross-sectional diameter of not more than 2.5 mm, wherein the mesh structure is formed of at least one mesh structural element which has a height that is no more than 200 m, in particular no more than 150 m, preferably no more than 70 m, where the height is measurable along a diameter of the mesh structure, and wherein the mesh structure is at least partially formed of a nickel titanium alloy and is at least partially coated in fibrin.

Compositions comprising electrospun fibers and pharmaceutical agents encapsulated thereto are provided. Further, articles such as medical devices and methods of use of said fibers, including, but not limited to coating of medical tubes, are provided.